|Publication number||US20090036948 A1|
|Application number||US 12/186,975|
|Publication date||5 Feb 2009|
|Filing date||6 Aug 2008|
|Priority date||8 Apr 2002|
|Also published as||US7162303, US7647115, US8131372, US8150518, US8880186, US8983595, US20030216792, US20050228459, US20050228460, US20050234523, US20070173899, US20120130345, US20130013024, US20130253603, US20140088561, US20150080872|
|Publication number||12186975, 186975, US 2009/0036948 A1, US 2009/036948 A1, US 20090036948 A1, US 20090036948A1, US 2009036948 A1, US 2009036948A1, US-A1-20090036948, US-A1-2009036948, US2009/0036948A1, US2009/036948A1, US20090036948 A1, US20090036948A1, US2009036948 A1, US2009036948A1|
|Inventors||Howard R. Levin, Mark Gelfand|
|Original Assignee||Ardian, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (162), Classifications (29), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application is related and claims priority to the following commonly-owned provisional applications: Ser. No. 60/370,190, entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the U.S. Patent and Trademark Office (USPTO) on Apr. 8, 2002; Ser. No. 60/415,575 entitled “Modulation Of Renal Nerve To Treat CHF”, that was filed in the USPTO on Oct. 3, 2002, and Ser. No. 60/442,970 entitled “Treatment Of Renal Failure And Hypertension”, that was filed in the USPTO on Jan. 29, 2003. The entirety of each of these provisional applications is incorporated by reference herein.
This invention relates to methods and apparatus for treatment of congestive heart failure, chronic renal failure and hypertension by nerve stimulation. In particular, the invention relates to the improvement of these conditions of patients by blocking signals to the renal (kidney) nerve.
The Heart Failure Problem:
Congestive Heart Failure (CHF) is a form of heart disease still increasing in frequency. According to the American Heart Association, CHF is the “Disease of the Next Millennium”. The number of patients with CHF is expected to grow even more significantly as an increasing number of the “Baby Boomers” reach 50 years of age. CHF is a condition that occurs when the heart becomes damaged and reduces blood flow to the organs of the body. If blood flow decreases sufficiently, kidney function becomes impaired and results in fluid retention, abnormal hormone secretions and increased constriction of blood vessels. These results increase the workload of the heart and further decrease the capacity of the heart to pump blood through the kidney and circulatory system. This reduced capacity further reduces blood flow to the kidney, which in turn further reduces the capacity of the blood. It is believed that the progressively-decreasing perfusion of the kidney is the principal non-cardiac cause perpetuating the downward spiral of the “Vicious Cycle of CHF”. Moreover, the fluid overload and associated clinical symptoms resulting from these physiologic changes are predominant causes for excessive hospital admissions, terrible quality of life and overwhelming costs to the health care system due to CHF.
While many different diseases may initially damage the heart, once present, CHF is split into two types: Chronic CHF and Acute (or Decompensated-Chronic) CHF. Chronic Congestive Heart Failure is a longer term, slowly progressive, degenerative disease. Over years, chronic congestive heart failure leads to cardiac insufficiency. Chronic CHF is clinically categorized by the patient's ability to exercise or perform normal activities of daily living (such as defined by the New York Heart Association Functional Class). Chronic CHF patients are usually managed on an outpatient basis, typically with drugs.
Chronic CHF patients may experience an abrupt, severe deterioration in heart function, termed Acute Congestive Heart Failure, resulting in the inability of the heart to maintain sufficient blood flow and pressure to keep vital organs of the body alive. These acute CHF deteriorations can occur when extra stress (such as an infection or excessive fluid overload) significantly increases the workload on the heart in a stable chronic CHF patient. In contrast to the stepwise downward progression of chronic CHF, a patient suffering acute CHF may deteriorate from even the earliest stages of CHF to severe hemodynamic collapse. In addition, Acute CHF can occur within hours or days following an Acute Myocardial Infarction (AMI), which is a sudden, irreversible injury to the heart muscle, commonly referred to as a heart attack.
Normal Kidney Function:
The kidneys are a pair of organs that lie in the back of the abdomen on each side of the vertebral column. Kidneys play an important regulatory role in maintaining the homeostatic balance of the body. The kidneys function like a complex chemical plant. The kidneys eliminate foreign chemicals from the body, regulate inorganic substances and the extracellular fluid, and function as endocrine glands, secreting hormonal substances like renin and erythropoietin.
The main functions of the kidney are to maintain the water balance of the body and control metabolic homeostasis. Healthy kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively. In case of renal disease, some normal and important physiological functions become detrimental to the patient's health. This process is called overcompensation. In the case of Chronic Renal Failure (CRF) patients overcompensation often manifests in hypertension (pathologically high blood pressure) that is damaging to heart and blood vessels and can result in a stroke or death.
The functions of the kidney can be summarized under three broad categories: a) filtering blood and excreting waste products generated by the body's metabolism; b) regulating salt, water, electrolyte and acid-base balance; and c) secreting hormones to maintain vital organ blood flow. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body.
The primary functional unit of the kidneys that is involved in urine formation is called the “nephron”. Each kidney consists of about one million nephrons. The nephron is made up of a glomerulus and its tubules, which can be separated into a number of sections: the proximal tubule, the medullary loop (loop of Henle), and the distal tubule. Each nephron is surrounded by different types of cells that have the ability to secrete several substances and hormones (such as renin and erythropoietin). Urine is formed as a result of a complex process starting with the filtration of plasma water from blood into the glomerulus. The walls of the glomerulus are freely permeable to water and small molecules but almost impermeable to proteins and large molecules. Thus, in a healthy kidney, the filtrate is virtually free of protein and has no cellular elements. The filtered fluid that eventually becomes urine flows through the tubules. The final chemical composition of the urine is determined by the secretion into and reabsorbtion of substances from the urine required to maintain homeostasis.
Receiving about 20% of cardiac output, the two kidneys filter about 125 ml of plasma water per minute. This is called the Glomerular Filtration Rate (GFR) and is the gold standard measurement of the kidney function. Since measurement of GFR is very cumbersome and expensive, clinically, the serum creatinine level or creatinine clearance are used as surrogates to measure kidney function. Filtration occurs because of a pressure gradient across the glomerular membrane. The pressure in the arteries of the kidney pushes plasma water into the glomerulus causing filtration. To keep the GFR relatively constant, pressure in the glomerulus is held constant by the constriction or dilatation of the afferent and efferent arterioles, the muscular walled vessels leading to and from each glomerulus.
Abnormal Kidney Function in CHF:
The kidneys maintain the water balance of the body and control metabolic homeostasis. The kidneys regulate the amount of fluid in the body by making the urine more or less concentrated, thus either reabsorbing or excreting more fluid, respectively. Without properly functioning kidneys, a patient will suffer water retention, reduced urine flow and an accumulation of wastes toxins in the blood and body. These conditions resulting from reduced renal function or renal failure (kidney failure) are believed to increase the workload of the heart. In a CHF patient, renal failure will cause the heart to further deteriorate as the water build-up and blood toxins accumulate due to the poorly functioning kidneys and in turn, cause the heart further harm.
In a CHF patient, for any of the known cause of heart dysfunction, the heart will progressively fail and blood flow and pressure will drop in the patients circulatory system. In the acute heart failure, the short-term compensations serve to maintain perfusion to critical organs, notably the brain and the heart that cannot survive prolonged reduction in blood flow. In chronic heart failure, these same responses that initially aided survival in acute heart failure can become deleterious.
A combination of complex mechanisms contribute to the deleterious fluid overload in CHF. As the heart fails and blood pressure drops, the kidneys cannot function owing to insufficient blood pressure for perfusion and become impaired. This impairment in renal function ultimately leads to a decrease in urine output. Without sufficient urine output, the body retains fluids and the resulting fluid overload causes peripheral edema (swelling of the legs), shortness of breath (from fluid in the lungs), and fluid in the abdomen, among other undesirable conditions in the patient.
In addition, the decrease in cardiac output leads to reduced renal blood flow, increased neurohormonal stimulus, and release of the hormone renin from the juxtaglomerular apparatus of the kidney. This results in avid retention of sodium and thus volume expansion. Increased rennin results in the formation of angiotensin, a potent vasoconstrictor.
Heart failure and the resulting reduction in blood pressure reduces the blood flow and perfusion pressure through organs in the body, other than the kidneys. As they suffer reduced blood pressure, these organs may become hypoxic causing the development of a metabolic acidosis which reduces the effectiveness of pharmacological therapy as well as increases the risk of sudden death.
This spiral of deterioration that physicians observe in heart failure patients is believed to be mediated, in large part, by activation of a subtle interaction between heart function and kidney function, known as the renin-angiotensin system. Disturbances in the heart's pumping function results in decreased cardiac output and diminished blood flow. The kidneys respond to the diminished blood flow as though the total blood volume was decreased, when in fact the measured volume is normal or even increased. This leads to fluid retention by the kidneys and formation of edema causing fluid overload and increased stress on the heart.
Systemically, CHF is associated with an abnormally elevated peripheral vascular resistance and is dominated by alterations of the circulation resulting from an intense disturbance of sympathetic nervous system function. Increased activity of the sympathetic nervous system promotes a downward vicious cycle of increased arterial vasoconstriction (increased resistance of vessels to blood flow) followed by a further reduction of cardiac output, causing even more diminished blood flow to the vital organs.
In CHF via the previously explained mechanism of vasoconstriction, the heart and circulatory system dramatically reduces blood flow to kidneys. During CHF, the kidneys receive a command from higher neural centers via neural pathways and hormonal messengers to retain fluid and sodium in the body. In response to stress on the heart, the neural centers command the kidneys to reduce their filtering functions. While in the short term, these commands can be beneficial, if these commands continue over hours and days they can jeopardize the persons life or make the person dependent on artificial kidney for life by causing the kidneys to cease functioning.
When the kidneys do not fully filter the blood, a huge amount of fluid is retained in the body resulting in bloating (fluid in tissues), and increases the workload of the heart. Fluid can penetrate into the lungs and the patient becomes short of breath. This odd and self-destructive phenomenon is most likely explained by the effects of normal compensatory mechanisms of the body that improperly perceive the chronically low blood pressure of CHF as a sign of temporary disturbance such as bleeding.
In an acute situation, the organism tries to protect its most vital organs, the brain and the heart, from the hazards of oxygen deprivation. Commands are issued via neural and hormonal pathways and messengers. These commands are directed toward the goal of maintaining blood pressure to the brain and heart, which are treated by the body as the most vital organs. The brain and heart cannot sustain low perfusion for any substantial period of time. A stroke or a cardiac arrest will result if the blood pressure to these organs is reduced to unacceptable levels. Other organs, such as kidneys, can withstand somewhat longer periods of ischemia without suffering long-term damage. Accordingly, the body sacrifices blood supply to these other organs in favor of the brain and the heart.
The hemodynamic impairment resulting from CHF activates several neurohormonal systems, such as the renin-angiotensin and aldosterone system, sympatho-adrenal system and vasopressin release. As the kidneys suffer from increased renal vasoconstriction, the filtering rate (GFR) of the blood drops and the sodium load in the circulatory system increases. Simultaneously, more renin is liberated from the juxtaglomerular of the kidney. The combined effects of reduced kidney functioning include reduced glomerular sodium load, an aldosterone-mediated increase in tubular reabsorption of sodium, and retention in the body of sodium and water. These effects lead to several signs and symptoms of the CHF condition, including an enlarged heart, increased systolic wall stress, an increased myocardial oxygen demand, and the formation of edema on the basis of fluid and sodium retention in the kidney. Accordingly, sustained reduction in renal blood flow and vasoconstriction is directly responsible for causing the fluid retention associated with CHF.
In view of the physiologic mechanisms described above it is positively established that the abnormal activity of the kidney is a principal non-cardiac cause of a progressive condition in a patient suffering from CHF.
Growing population of late stage CHF patients is an increasing concern for the society. The disease is progressive, and as of now, not curable. The limitations of drug therapy and its inability to reverse or even arrest the deterioration of CHF patients are clear. Surgical therapies are effective in some cases, but limited to the end-stage patient population because of the associated risk and cost. There is clearly a need for a new treatment that will overcome limitations of drug therapy but will be less invasive and costly than heart transplantation.
Similar condition existed several decades ago in the area of cardiac arrhythmias. Limitations of anti-arrhythmic drugs were overcome by the invention of heart pacemakers. Widespread use of implantable electric pacemakers resulted in prolonged productive life for millions of cardiac patients. So far, all medical devices proposed for the treatment of CHF are cardio-centric i.e., focus on the improvement of the heart function. The dramatic role played by kidneys in the deterioration of CHF patients has been overlooked by the medical device industry.
Neural Control of Kidneys:
The autonomic nervous system is recognized as an important pathway for control signals that are responsible for the regulation of body functions critical for maintaining vascular fluid balance and blood pressure. The autonomic nervous system conducts information in the form of signals from the body's biologic sensors such as baroreceptors (responding to pressure and volume of blood) and chemoreceptors (responding to chemical composition of blood) to the central nervous system via its sensory fibers. It also conducts command signals from the central nervous system that control the various innervated components of the vascular system via its motor fibers.
Experience with human kidney transplantation provided early evidence of the role of the nervous system in the kidney function. It was noted that after the transplant, when all the kidney nerves are totally severed, the kidney increased the excretion of water and sodium. This phenomenon was also observed in animals when the renal nerves were cut or chemically destroyed. The phenomenon was called “denervation diuresis” since the denervation acted on a kidney similar to a diuretic medication. Later the “denervation diuresis” was found to be associated with the vasodilatation the renal arterial system that led to the increase of the blood flow through the kidney. This observation was confirmed by the observation in animals that reducing blood pressure supplying the kidney could reverse the “denervation diuresis”.
It was also observed that after several months passed after the transplant surgery in successful cases, the “denervation diuresis” in transplant recipients stopped and the kidney function returned to normal. Originally it was believed that the “renal diuresis” is a transient phenomenon and that the nerves conducting signals from the central nervous system to the kidney are not essential for the kidney function. Later, new discoveries led to the different explanation. It is believed now that the renal nerves have a profound ability to regenerate and the reversal of the “denervation diuresis” shall be attributed to the growth of the new nerve fibers supplying kidneys with the necessary stimuli.
Another body of research that is of particular importance for this application was conducted in the period of 1964-1969 and focused on the role of the neural control of secretion of the hormone renin by the kidney. As was discussed previously, renin is a hormone responsible for the “vicious cycle” of vasoconstriction and water and sodium retention in heart failure patients. It was demonstrated that increase (renal nerve stimulation) or decrease (renal nerve denervation) in renal sympathetic nerve activity produced parallel increases and decreases in the renin secretion rate by the kidney, respectively.
In summary, it is known from clinical experience and the large body of animal research that the stimulation of the renal nerve leads to the vasoconstriction of blood vessels supplying the kidney, decreased renal blood flow, decreased removal of water and sodium from the body and increased renin secretion. These observations closely resemble the physiologic landscape of the deleterious effects of the chronic congestive heart failure. It is also known that the reduction of the sympathetic renal nerve activity, achieved by denervation, can reverse these processes.
It was established in animal models that the heart failure condition results in the abnormally high sympathetic stimulation of the kidney. This phenomenon was traced back to the sensory nerves conducting signals from baroreceptors to the central nervous system. Baroreceptors are the biologic sensors sensitive to blood pressure. They are present in the different locations of the vascular system. Powerful relationship exists between the baroreceptors in the carotid arteries (supplying brain with arterial blood) and the sympathetic nervous stimulus to the kidneys. When the arterial blood pressure was suddenly reduced in experimental animals with heart failure, the sympathetic tone increased. Nevertheless the normal baroreflex alone, cannot be responsible for the elevated renal nerve activity in chronic CHF patients. If exposed to the reduced level of arterial pressure for a prolonged time baroreceptors normally “reset” i.e. return to the baseline level of activity until a new disturbance is introduced. Therefore, in chronic CHF patients the components of the autonomic nervous system responsible for the control of blood pressure and the neural control of the kidney function become abnormal. The exact mechanisms that cause this abnormality are not fully understood but, its effects on the overall condition of the CHF patients are profoundly negative.
End Stage Renal Disease Problem:
There is a dramatic increase in patients with end-stage renal disease (ESRD) due to diabetic nephropathy, chronic glomerulonephritis and uncontrolled hypertension. In the US alone, 372,000 patients required dialysis in the year 2000. There were 90,000 new cases of ESRD in 1999 with the number of patients on dialysis is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. Mortality in patients with ESRD remains 10-20 times higher than that in the general population. Annual Medicare patient costs $52,868 for dialysis and $18,496 for transplantation. The total cost for Medicare patients with ESRD in 1998 was $12.04 billion.
The primary cause of these problems is the slow relentless progression of Chronic Renal Failure (CRF) to ESRD. CRF represents a critical period in the evolution of ESRD. The signs and symptoms of CRF are initially minor, but over the course of 2-5 years, become progressive and irreversible. Until the 1980's, there were no therapies that could significantly slow the progression of CRF to ESRD. While some progress has been made in combating the progression to and complications of ESRD in last two decades, the clinical benefits of existing interventions remain limited with no new drug or device therapies on the horizon.
Progression of Chronic Renal Failure:
It has been known for several decades that renal diseases of diverse etiology (hypotension, infection, trauma, autoimmune disease, etc.) can lead to the syndrome of CRF characterized by systemic hypertension, proteinuria (excess protein filtered from the blood into the urine) and a progressive decline in GFR ultimately resulting in ESRD. These observations suggested that CRF progresses via a common pathway of mechanisms, and that therapeutic interventions inhibiting this common pathway may be successful in slowing the rate of progression of CRF irrespective of the initiating cause.
To start the vicious cycle of CRF, an initial insult to the kidney causes loss of some nephrons. To maintain normal GFR, there is an activation of compensatory renal and systemic mechanisms resulting in a state of hyperfiltration in the remaining nephrons. Eventually, however, the increasing numbers of nephrons “overworked” and damaged by hyperfiltration are lost. At some point, a sufficient number of nephrons are lost so that normal GFR can no longer be maintained. These pathologic changes of CRF produce worsening systemic hypertension, thus high glomerular pressure and increased hyperfiltration. Increased glomerular hyperfiltration and permeability in CRF pushes an increased amount of protein from the blood, across the glomerulus and into the renal tubules. This protein is directly toxic to the tubules and leads to further loss of nephrons, increasing the rate of progression of CRF. This vicious cycle of CRF continues as the GFR drops, with loss of additional nephrons leading to further hyperfiltration and eventually to ESRD requiring dialysis. Clinically, hypertension and excess protein filtration have been shown to be two major determining factors in the rate of progression of CRF to ESRD.
Though previously clinically known, it was not until the 1980s that the physiologic link between hypertension, proteinuria, nephron loss and CRF was identified. In 1990s the role of sympathetic nervous system activity was elucidated. Afferent signals arising from the damaged kidneys due to the activation of mechanoreceptors and chemoreceptors stimulate areas of the brain responsible for blood pressure control. In response brain increases sympathetic stimulation on the systemic level resulting in the increased blood pressure primarily through vasoconstriction of blood vessels.
When elevated sympathetic stimulation reaches the kidney via the efferent sympathetic nerve fibers, it produces major deleterious effects in two forms:
A. Kidney is damaged by direct renal toxicity from the release of sympathetic neurotransmitters (such as norepinephrine) in the kidney independent of the hypertension.
B. Secretion of renin that activates Angiotensin II is increased leading to the increased systemic vasoconstriction and exacerbated hypertension.
Over time damage to the kidney leads to further increase of afferent sympathetic signals from the kidney to the brain. Elevated Angiotensin II further facilitates internal renal release of neurotransmitters. The feedback loop is therefore closed accelerating the deterioration of the kidney.
A treatment of heart failure, renal failure and hypertension has been developed to arrest or slow down the progression of the disease. This treatment is expected to delay the morbid conditions and death often suffered by CHF patients and to delay the need for dialysis in renal failure. This treatment is expected to control hypertension in patients that do not respond to drugs or require multiple drugs.
The treatment includes a device and method that reduces the abnormally elevated sympathetic nerve signals that contribute to the progression of heart and renal disease. The desired treatment should be implemented while preserving a patient's mobility and quality of life without the risk of major surgery.
The treatment breaks with tradition and proposes a counterintuitive novel method and apparatus of treating heart failure, renal failure and hypertension by electrically or chemically modulating the nerves of the kidney. Elevated nerve signals to and from the kidney are a common pathway of the progression of these chronic conditions.
Chronic heart and renal failure is treated by reducing the sympathetic efferent or afferent nerve activity of the kidney. Efferent nerves (as opposed to afferent) are the nerves leading from the central nervous system to the organ, in this case to the kidney. Sympathetic nervous system (as opposed to parasympathetic) is the part of the autonomic nervous system that is concerned especially with preparing the body to react to situations of stress or emergency that tends to depress secretion, decrease the tone and contractility of smooth muscle, and increase heart rate. In the case of renal sympathetic activity, it is manifested in the inhibition of the production of urine and excretion of sodium. It also elevates the secretion of renin that triggers vasoconstriction. This mechanism is best illustrated by the response of the body to severe bleeding. When in experimental animals, the blood pressure is artificially reduced by bleeding, and the sympathetic inhibition of the kidney is increased to maintain blood pressure with an ultimate goal of preserving the brain from hypotension. The resulting vasoconstriction and fluid retention work in synchrony to help the body to maintain homeostasis.
Efferent renal nerve activity is considered postganglionic, autonomic and exclusively sympathetic. In general, efferent sympathetic nerves can cause a variety of responses in the innervated organs. Studies of sympathetic renal nerves show that they have a strong tendency to behave as a uniform population that acts as vasoconstrictors. The renal postganglionic neurons are modulated by pregangleonic (ganglion is a “knot” or agglomeration of nerve sells) nerves that originate from the brain and thoracic and upper lumbar regions of the spinal cord.
The pregangleonic nerves have diverse function and are likely to have high degree of redundancy. Although different pathways exist to achieve reduced efferent renal nerve activity, the simplest way is to denervate the postganglionic nerves with an electric stimulus or a chemical agent. The same desired affect could be achieved by total surgical, electric or chemical destruction (ablation) of the nerve. For two reasons this is not a preferred pathway. As was described before, renal nerves regenerate and can grow back as soon as several months after surgery. Secondarily, total irreversible denervation of the kidney can result in danger to the patient. Overdiuresis or removal of excess water from blood can result in the reduction of blood volume beyond the amount that can be rapidly replaced by fluid intake. This can result in hypovolemia and hypotension. Hypotension is especially dangerous in heart failure patients with the reduced capacity of the heart to pump blood and maintain blood pressure. In addition, the vasodilation of the renal artery resulting from the renal denervation will cause a significant increase in renal blood flow. In a healthy person, renal blood flow can amount to as much as 20% of the total cardiac output. In heart failure patients cardiac output is reduced and the renal denervation can “steal” even larger fraction of it from circulation. This, in turn, can lead to hypotension. Also, in a heart failure patient the heart has limited ability to keep up with the demand for oxygenated blood that can be caused by even modest physical effort. Therefore a heart failure patient that can sustain the increased blood flow to the kidneys while at rest can face serious complications resulting from acute hypotension, if the demand for blood flow is increased by temperature change or exercise.
In view of the factors described above it is desired to have means to reduce the efferent sympathetic stimulation of the kidney in CHF patients in a reversible, controlled fashion preferably based on a physiologic feedback signal that is indicative of the oxygen demand by the body, blood pressure, cardiac output of the patient or a combination of these and other physiologic parameters.
The treatment also breaks with tradition and proposes a counterintuitive novel method and apparatus of treating chronic renal failure (CRF) with the goal of slowing down the progression of CRF to the ESRD by electrically or chemically altering the sympathetic neural stimulation entering and exiting the kidney. The described method and apparatus can be also used to treat hypertension in patients with renal disease or abnormal renal function.
To control the afferent nerve signals from the kidney to the brain and block efferent nerve stimuli from entering the kidney (without systemic side effects of drug therapy), a renal nerve stimulator is implanted and attached to an electrode lead placed around or close to the renal artery. Stimulation effectively blocks or significantly reduces both efferent and afferent signals traveling between the kidney, the autonomic nervous system and the central nervous system.
The benefits that may be possible by controlling renal nerve signals to reduce efferent overstimulation are:
a. The secretion of renin by kidney should be reduced by 40-50% translating into the proportionate reduction of systemic angiotensin II, resulting in the reduction of blood pressure in all hypertensive patients including patients refractory to drugs.
b. Similar to renoprotective mechanisms of ACE-I, the reduction of angiotensin II should result in slowed progression of intrarenal changes in glomerular structure and function independent of blood pressure control.
c. Similar to the effects of moxonidine, reduced efferent overstimulation should reduce damage by direct renal toxicity from the release of sympathetic neurotransmitters.
Following the reduction of the afferent sympathetic renal feedback to the brain, there is expected to be a marked reduction in the systemic efferent overstimulation. This will translate into the systemic vasodilation and reduction of hypertension independent of the renin-angiotensin II mechanism.
Renal nerve stimulation in hypertensive CRF patients is unlikely to cause clinically relevant episodes of hypotension. Systemic blood pressure is tightly controlled by feedbacks from baroreceptors in aorta and carotid sinuses. These mechanisms are likely to take over if the blood pressure becomes too low. In polycystic kidney disease (PKD) patients who underwent surgery for total denervation of kidneys, denervation resolved hypertension without postoperative episodes of hypotension.
Technique for Nerve Modulation
Nerve activity can be reversibly modulated in several different ways. Nerves can be stimulated with electric current or chemicals that enhance or inhibit neurotransmission. In the case of electrical stimulation, a stimulator containing a power source is typically connected to the nerve by wires or leads. Leads can terminate in electrodes, cuffs that enclose the nerve or in conductive anchors (screws or hooks) that are embedded in tissue. In the later case, the lead is designed to generate sufficient electric field to alter or induce current in the nerve without physically contacting it. The electrodes or leads can by bipolar or unipolar. There are permanent leads that are implanted for months and years to treat a chronic condition and temporary leads used to support the patient during an acute stage of the disease. The engineering aspects of design and manufacturing of nerve stimulators, pacemakers, leads, anchors and nerve cuffs are well known.
Proposed clinical applications of nerve stimulation include: Depression, Anxiety, Alzheimer's Disease, Obesity, and others. In all existing clinical applications except pain control, the targeted nerves are stimulated to increase the intensity of the transmitted signal. To achieve relief of hypertension and CRF signal traffic traveling to and from the kidney via renal nerves needs to be reduced. This can be achieved by known methods previously used in physiologic studies on animals. A nerve can be paced with electric pulses at high rate or at voltage that substantially exceed normal traffic. As a result, a nerve will be “overpaced”, run out of neurotransmitter substance and transmit less stimulus to the kidney. Alternatively relatively high voltage potential can be applied to the nerve to create a blockade. This method is known as “voltage clamping” of a nerve. Infusion of a small dose of a local anesthetic in the vicinity of the nerve will produce the same effect.
Ablation of conductive tissue pathways is another commonly used technique to control aterial or ventricular tachycardia of the heart. Ablation can be performed by introduction of a catheter into the venous system in close proximity of the sympathetic renal nerve subsequent ablation of the tissue. Catheter based ablation devices were previously used to stop electric stimulation of nerves by heating nerve tissue with RF energy that can be delivered by a system of electrodes. RF energy thus delivered stops the nerve conduction. U.S. Pat. No. 6,292,695 describes in detail a method and apparatus for transvascular treatment of tachycardia and fibrillation with nerve stimulation and ablation. Similar catheter based apparatus can be used to ablate the renal nerve with an intent to treat CRF. The method described in this invention is applicable to irreversible ablation of the renal nerve by electric energy, cold, or chemical agents such as phenol or alcohol.
Thermal means may be used to cool the renal nerve and adjacent tissue to reduce the sympathetic nerve stimulation of the kidney. Specifically, the renal nerve signals may be dampened by either directly cooling the renal nerve or the kidney, to reduce their sensitivity, metabolic activity and function, or by cooling the surrounding tissue. An example of this approach is to use the cooling effect of the Peltier device. Specifically, the thermal transfer junction may be positioned adjacent the vascular wall or a renal artery to provide a cooling effect. The cooling effect may be used to dampen signals generated by the kidney. Another example of this approach is to use the fluid delivery device to deliver a cool or cold fluid (e.g. saline).
A preferred embodiment and best mode of the invention is illustrated in the attached drawings that are described as follows:
A method and apparatus has been developed to regulate sympathetic nerve activity to the kidney to improve a patient's renal function and overall condition, and ultimately to arrest or reverse the vicious cycle of CHF disease.
In the kidney 111 efferent sympathetic nerve stimulation 109 causes retention of water (reduction of the amount of urine) and retention of sodium 112 an osmotic agent that is responsible for the expansion of blood volume. The sympathetic stimulation of the kidney stimulates the release of hormones renin 105 and angiotensin II. These hormones activate the complex renin-angiotensin-aldosterone system 117 leading to more deleterious hormones causing vasoconstriction 104 and heart damage 116. The sympathetic stimulation of the hypothalamus of the brain 102 results in the release of the powerful hormone vasopressin 114 that causes further vasoconstriction of blood vessels. Angiotensin II constricts blood vessels and stimulates the release of aldosterone from adrenal gland (not shown). It also increases tubular sodium reabsorption (sodium retention) in the kidney 111 and causes remodeling of cardiac myocytes therefore contributing to the further deterioration of the heart 103 and the kidney 111.
It can be inferred from the
An example of an implantable drug infusion device is the MiniMed 2007™ implantable insulin pump system for treatment of diabetes or the SynchroMed Infusion System used to control chronic pain, both manufactured by Medtronic Inc. The drug used in this embodiment can be a common local anesthetic such as Novocain or Lidocaine or a more long lasting equivalent anesthetic. Alternatively, a nerve toxin such as the botox can be used to block the nerve. An example of an implantable nerve stimulator is the Vagus Nerve Stimulation (VNS™) with the Cyberonics NeuroCybernetic Prosthesis (NCP®) System used for treatment of epilepsy. It is manufactured by Cyberonics Inc. The internal mechanism of the implantable device typically includes a battery, an electronic circuit and (in the case of a drug delivery device), a reservoir with medication. Neurostimulation systems from different manufacturers are virtually identical across application areas, usually varying only in the patterns of stimulating voltage pulses, style or number of electrodes used, and the programmed parameters. The basic implantable system consists of a pacemaker-like titanium case enclosing the power source and microcircuitry that are used to create and regulate the electrical impulses. An extension lead attached to this generator carries the electrical pulses to the electrode lead that is implanted or attached to the nerves or tissues to be stimulated.
The implantable device 202 is equipped with the lead 204 connecting it to the renal nerve 205. The lead can contain an electric wire system or a catheter for delivery of medication or both. Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208. Sympathetic trunk is connected to the patient's spinal cord inside the spine 207. The connection can be located between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10th, 11th and 12th thoracic and 1st lumbar segments of the spine 207.
The implantable device 202 is also equipped with the sensor lead 209 terminated with the sensor 210. The sensor can be a pressure sensor or an oxygen saturation sensor. The sensor 210 can be located in the left ventricle of the heart 211, right atrium of the heart or other cavity of the heart. It can also be located outside of the heart in the aorta 213, the aortic arch 212 or a carotid artery 214. If the sensor is a pressure sensor, it is used to supply the device 202 with the information necessary to safely regulate the sympathetic nerve signals to the kidney 208. A venous blood oxygen saturation signal can be used in a similar way to control the sympathetic nerve traffic based on oxygen demand. The sensor will be placed in the right atrium of the heart or in the vena cava. More than one sensor can be used in combination to supply information to the device. Sensors can be inside the vascular system (blood vessels) or outside of it. For example, a motion sensor can be used to detect activity of the person. Such sensor does not require placement outside the implanted device case and can be integrated inside the sealed case of the device 202 as a part of the internal mechanism.
Two potential uses for the embodiment shown on
Similar to the venous embodiment, an arterial system can be used. Catheter will be introduced via the femoral artery and aorta (not shown) into the renal artery 307. Arterial catheterization is more dangerous than venous but may achieve superior result by placing stimulation electrode (or electrodes) in close proximity to the renal nerve without surgery.
Clinically used spiral cuffs for connecting to a nerve are manufactured by Cyberonics Inc. (Houston, Tex.) that also manufactures a fully implantable nerve stimulator operating on batteries. See also, e.g., U.S. Pat. No. 5,251,643. Various external signal generators suitable for nerve stimulation are available from Grass-Telefactor Astro-Med Product Group (West Warwick, R.I.). Nerve cuff electrodes are well known. See, e.g., U.S. Pat. No. 6,366,815. The principle of the anodal block is based on the observation that close to an anodal electrode contact the propagation of a nerve action potential can be blocked due to hyperpolarization of the fiber membrane. See e.g., U.S. Pat. Nos. 5,814,079 and 5,800,464. If the membrane is sufficiently hyperpolarized, action potentials cannot pass the hyperpolarized zone and are annihilated.
As large diameter fibers need a smaller stimulus for their blocking than do small diameter fibers, a selective blockade of the large fibers is possible. See e.g., U.S. Pat. No. 5,755,750. The activity in different fibers of a nerve in an animal can be selectively blocked by applying direct electric current between an anode and a cathode attached to the nerve.
Antidromic pulse generating wave form for collision blocking is an alternative means of inducing a temporary electric blockade of signals traveling along nerve fibers. See e.g., U.S. Pat. No. 4,608,985. In general, nerve traffic manipulation techniques such as anodal blocking, cathodal blocking and collision blocking are sufficiently well described in scientific literature and are available to an expert in neurology. Most of blocking methods allow sufficient selectivity and reversibility so that the nerve will not be damaged in the process of blocking and that selective and gradual modulation or suppression of traffic in different functional fibers can be achieved.
A nerve is composed of the axons of a large number of individual nerve fibers. A large nerve, such as a renal nerve, may contain thousands of individual nerve fibers, both myelinated and non-myelinated. Practical implementation of physiological blockade of selective nerve fibers in a living organism is illustrated by the paper “Respiratory responses to selective blockade of carotid sinus baroreceptors in the dog” by Francis Hopp. Both anodal block and local anesthesia by injection of bupivacaine (a common long-acting local anaesthetic, used for surgical anaesthesia and acute pain management) were applied to the surgically isolated and exposed but intact nerve leading from baroreceptors (physiologic pressure sensors) in the carotid sinus of the heart to the brain of an animal. Anodal block was induced using simple wire electrodes. Experiments showed that by increasing anodal blocking current from 50 to 350 microamperes signal conduction in C type fibers was gradually reduced from 100% to 0% (complete block) in linear proportion to the strength of the electric current. Similarly increasing concentration of injected bupivacaine (5, 10, 20 and 100 mg/ml) resulted in gradual blocking of the carotid sinus nerve activity in a dog. These experiments confirmed that it is possible to reduce intensity of nerve stimulation (nerve traffic) in an isolated nerve in controllable, reversible and gradual was by the application of electric current or chemical blockade. In the same paper it was described that smaller C type fibers were blocked by lower electric current and higher concentration of bupivacaine than larger C type fibers.
Gerald DiBona in “Neural control of the kidney: functionally specific renal sympathetic nerve fibers” described the structure and role of individual nerve fibers controlling the kidney function. Approximately 96% of sympathetic renal fibers in the renal nerve are slow conducting unmyelinated C type fibers 0.4 to 2.5 micrometers in diameter. Different fibers within this range carry different signals and respond to different levels of stimulation and inhibition. It is known that lower stimulation voltage of the renal nerve created untidiuretic effect (reduced urine output) while higher level of stimulation created vasoconstriction effect. Stimulation threshold is inversely proportional to the fiber diameter; therefore it is likely that elevated signal levels in larger diameter renal nerve C fibers are responsible for the retention of fluid in heart failure. Relatively smaller diameter C fibers are responsible for vasoconstriction resulting in the reduction of renal blood flow in heart failure.
In clinical practice, it may be desired to modulate or block selectively or preferably the larger fibers 705. This can be achieved with lower levels of stimulation. The patient can be relieved of access fluid without significantly increasing renal blood flow since traffic in smaller C fibers will not be altered. Renal blood flow can amount to as much as 20% of cardiac output. In a CHF patient with a weakened heart significant increase of renal blood flow can lead to a dangerous decrease of arterial pressure if the diseased heart fails to pump harder to keep up with an increased demand for oxygenated blood. The nerve stimulator or signal generator 306 therefore is capable of at least two levels of stimulation: first (lower) level to block or partially block signals propagating in larger C fibers that control diuresis, and second (higher) level to block signals propagating in smaller C fibers that control renal vascular resistance and blood flow to the kidney. The later method of nerve traffic modulation with higher electric current levels is useful in preventing damage to kidneys in acute clinical situations where the vasoconstricton can lead to the ischemia of a kidney, acute tubular necrosis (ATN), acute renal failure and sometimes permanent kidney damage. This type of clinical scenario is often associated with the acute heart failure when hypotension (low blood pressure) results from a severe decompensation of a chronic heart failure patient. Acute renal failure caused by low blood flow to the kidneys is the most costly complication in patients with heart failure.
Similar differentiated response to modulation could be elicited by applying different frequency of electric pulses (overpacing) to the renal nerve and keeping the applied voltage constant. DiBona noted that renal fibers responsible for rennin secretion responded to the lowest frequency of pulses (0.5 to 1 Hz), fibers responsible for sodium retention responded to middle range of frequencies (1 to 2 Hz) and fibers responsible for blood flow responded to the highest frequency of stimulation (2 to 5 Hz). This approach can be used when the renal nerve block is achieved by overpacing the renal nerve by applying rapid series of electric pulses to the electrodes with the intent to fatigue the nerve to the point when it stops conducting stimulation pulses.
One embodiment of the method of treating heart failure comprises the following steps:
A. Introducing one or more electrodes in the close proximity with the renal nerve,
B. Connecting the electrodes to an electric stimulator or generator with conductive leads or wires,
C. Initiating flow of electric current to the electrodes sufficient to block or reduce signal traffic in the sympathetic efferent renal nerve fibers with the intention of increasing diuresis, reducing renal secretion of renin and vasodilation of the blood vessels in the kidney to increase renal blood supply.
After the cut is made in the umbilical area a special needle is inserted to start insufflation. A pressure regulated CO2 insufflator is connected to the needle. After satisfactory insuflation the needle is removed and a trocar is inserted through the previous small wound. This method reduces the recovery time due to its minimal tissue damage permitting the patient to return to normal activity in a shorter period of time. Although this type of procedure is known since the beginning of the 19th. century, it was not until the advent of high resolution video camera that laparoscopic surgery became very popular among surgeons. Kidney surgery including removal of donor kidneys is routinely done using laparoscopic methodology. It should be easy for a skilled surgeon to place the lead 903 through a tunnel in tissue layers 1001 surrounding the renal nerve 601. This way lead electrodes 905 and 906 are placed in close proximity to the nerve and can be used to induce a block without major surgery.
The effect of the invented therapeutic intervention will be the reduction of central (coming from the brain) sympathetic stimulation 1206 to all organs and particularly blood vessels that causes vasoconstriction and elevation of blood pressure. Following that hypertension 1205 will be reduced therefore reducing continuous additional insult to the kidney and other organs.
Invented therapy reduces or eliminates critical pathways of the progressive disease by blocking afferent 1306 and efferent 1307 signals to and from the kidney 1302. Both neurological 1311 and hormonal 1309 stimulus of vasoconstriction are therefore reduced resulting in the relief of hypertension 1304. As a result, over time the progression of renal disease is slowed down, kidney function is improved and the possibility of stroke from high blood pressure is reduced.
The lead conduit can be alternatively an electric wire or a catheter for delivery of medication or a combination of both. Renal nerve conducts efferent sympathetic stimulation from the sympathetic trunk 206 to the kidney 208. Sympathetic trunk is connected to the patient's spinal cord inside the spine 207. The lead to nerve connection can be located anywhere between the kidney 208 and the posterior renal or other renal ganglia (not shown) in the region of the 10th, 11th and 12th thoracic and 1st lumbar segments of the spine 207. The stimulation lead 204 and the arterial nerve cuff 1401, as selected for the preferred embodiment of the invention, can be placed using laparoscopic surgery.
To overcome this anatomic limitation the preferred embodiment of the neurostimulation shown on
Common to all the embodiments, is that an invasive device is used to decrease the level of renal nerve signals that are received by the kidney or generated by the kidney and received by the brain. The invention has been described in connection with the best mode now known to the applicant inventors. The invention is not to be limited to the disclosed embodiment. Rather, the invention covers all of various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
Heart failure, also called congestive heart failure (CHF) and chronic heart failure is a progressive heart disease characterized by low cardiac output, deterioration of heart muscle and fluid retention. Renal failure, also called chronic renal failure (CRF) is a progressive degenerative renal disease that is characterized by gradual loss of renal function that leads to the end stage renal disease (ESRD). ESRD requires dialysis for life. Hypertension is the chronic disease associated with high probability of stroke, renal failure and heart failure that is characterized by the abnormally high blood pressure.
A nerve in the context of this application means a separate nerve or a nerve bundle, nerve fiber, nerve plexus or nerve ganglion. Renal nerve is a part of the autonomic nervous system that forms a plexus on the external surface renal artery. Fibers contributing to the plexus arise from the celiac ganglion, the lowest splanchnic nerve, the aorticorenal ganglion and aortic plexus. The plexus is distributed with branches of the renal artery to blood vessels of the kidney, the glomeruli and tubules. The nerves from these sources, have a few ganglia developed upon them. They accompany the branches of the renal artery into the kidney; some filaments are distributed to the spermatic plexus and, on the right side, to the inferior vena cava.
Nerve simulation, neurostimulation, nerve modulation and neuromodulation are equivalent and mean altering (reducing or increasing) naturally occurring level of electric signals propagating through the nerve. The electric signal in the nerve is also called nerve traffic, nerve tone or nerve stimulus.
Nerve block, blocking or blockade is a form of neuromodulation and means the reduction or total termination of the propagation or conduction of the electric signal along the selected nerve. Nerve block can be pharmacological (induced by a drug or other chemical substance) or an electric block by electrostimulation. Electric nerve block can be a hyperpolarization block, cathodal, anodal or collision block. Overpacing a nerve can also induce a block. Overpacing means stimulating the nerve with rapid electric pulses at a rate that exceeds the natural cycling rate of the nerve polarization and depolarization. As a result of overpacing the nerve gets fatigued, reserves of the immediately available neurotransmitter substance in the nerve become exhausted, and the nerve becomes temporarily unable to conduct signals. Nerve block by the means listed above can result in the reduction of the nerve signal, in particular the renal sympathetic efferent or afferent tone that determines the electric stimulus received or generated by the kidney. The technique of the controlled reduction of the nerve signal or traffic, which results in less organ stimulation, is called nerve signal modulation. Nerve modulation means that the individual nerve fibers fire with a reduced frequency or that fewer of the nerve fibers comprising the renal nerve are actively conducting or firing. The increase of nerve traffic or nerve activity usually involves recruitment of larger number of fibers in the nerve; alternatively less stimulation is associated with less active fibers. Denervation means blocking of the renal nerve conduction or the destruction of the renal nerve.
Lead is a medical device used to access the nerve designated for stimulation or blocking. It is usually a tubular device that is electrically insulated and includes multiple conductors or wires. Wires conduct stimulation or blocking signals from the stimulator to the designated nerve. Wires are terminated in electrodes. Electrodes are conductive terminals and can contact the nerve directly or contact the conductive tissue in the vicinity of the nerve. Electrodes can have different geometric configurations and can be made of different materials. The lead can include lumens or tubes for drug delivery to the nerve. A stimulator or an electrostimulator is an electric device used to generate electric signals that are conducted by the lead to the nerve. The stimulator can be implanted in the body or external. Electric signals can be a DC current, voltage, series of pulses or AC current or voltage. Electrodes can induce an electric field that affects the nerve and results in nerve blocking. Nerve cuff is a support structure that at least partially envelops the targeted nerve.
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8088127||8 May 2009||3 Jan 2012||Innovative Pulmonary Solutions, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8131371||13 Apr 2006||6 Mar 2012||Ardian, Inc.||Methods and apparatus for monopolar renal neuromodulation|
|US8131372||19 Mar 2007||6 Mar 2012||Ardian, Inc.||Renal nerve stimulation method for treatment of patients|
|US8137274||11 Feb 2011||20 Mar 2012||Kona Medical, Inc.||Methods to deliver high intensity focused ultrasound to target regions proximate blood vessels|
|US8145316||25 Jul 2005||27 Mar 2012||Ardian, Inc.||Methods and apparatus for renal neuromodulation|
|US8145317||6 Mar 2006||27 Mar 2012||Ardian, Inc.||Methods for renal neuromodulation|
|US8150519||6 Mar 2006||3 Apr 2012||Ardian, Inc.||Methods and apparatus for bilateral renal neuromodulation|
|US8150520||6 Mar 2006||3 Apr 2012||Ardian, Inc.||Methods for catheter-based renal denervation|
|US8167805||19 Oct 2006||1 May 2012||Kona Medical, Inc.||Systems and methods for ultrasound applicator station keeping|
|US8172827||1 Jun 2006||8 May 2012||Innovative Pulmonary Solutions, Inc.||Apparatus for treating asthma using neurotoxin|
|US8175711||6 Mar 2006||8 May 2012||Ardian, Inc.||Methods for treating a condition or disease associated with cardio-renal function|
|US8226638||26 Sep 2011||24 Jul 2012||Innovative Pulmonary Solutions, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8277398||11 Feb 2011||2 Oct 2012||Kona Medical, Inc.||Methods and devices to target vascular targets with high intensity focused ultrasound|
|US8295912||23 Oct 2012||Kona Medical, Inc.||Method and system to inhibit a function of a nerve traveling with an artery|
|US8347891||14 Nov 2006||8 Jan 2013||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen|
|US8372009||26 Sep 2011||12 Feb 2013||Kona Medical, Inc.||System and method for treating a therapeutic site|
|US8374674||1 Feb 2011||12 Feb 2013||Kona Medical, Inc.||Nerve treatment system|
|US8388535||21 Jan 2011||5 Mar 2013||Kona Medical, Inc.||Methods and apparatus for focused ultrasound application|
|US8433423||13 Dec 2010||30 Apr 2013||Ardian, Inc.||Methods for multi-vessel renal neuromodulation|
|US8444640||14 Sep 2012||21 May 2013||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen|
|US8454594||11 Aug 2009||4 Jun 2013||Medtronic Ardian Luxembourg S.A.R.L.||Apparatus for performing a non-continuous circumferential treatment of a body lumen|
|US8463376||7 Jun 2011||11 Jun 2013||Guy P. Curtis||System and method for transvascular activation of cardiac nerves with automatic restart|
|US8469904||15 Mar 2011||25 Jun 2013||Kona Medical, Inc.||Energetic modulation of nerves|
|US8473067||10 Jun 2011||25 Jun 2013||Boston Scientific Scimed, Inc.||Renal denervation and stimulation employing wireless vascular energy transfer arrangement|
|US8480581||23 Mar 2010||9 Jul 2013||Cardiac Pacemakers, Inc.||Systems and methods for anemia detection, monitoring, and treatment|
|US8483831||17 Feb 2009||9 Jul 2013||Holaira, Inc.||System and method for bronchial dilation|
|US8489192||14 Jun 2012||16 Jul 2013||Holaira, Inc.||System and method for bronchial dilation|
|US8504147||25 Sep 2009||6 Aug 2013||Medtronic Ardian Luxembourg S.A.R.L.||Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction|
|US8512262||27 Jun 2012||20 Aug 2013||Kona Medical, Inc.||Energetic modulation of nerves|
|US8517962||15 Mar 2011||27 Aug 2013||Kona Medical, Inc.||Energetic modulation of nerves|
|US8548600||14 Sep 2012||1 Oct 2013||Medtronic Ardian Luxembourg S.A.R.L.||Apparatuses for renal neuromodulation and associated systems and methods|
|US8551069||6 Mar 2006||8 Oct 2013||Medtronic Adrian Luxembourg S.a.r.l.||Methods and apparatus for treating contrast nephropathy|
|US8556834||13 Dec 2010||15 Oct 2013||Kona Medical, Inc.||Flow directed heating of nervous structures|
|US8568399||7 Mar 2013||29 Oct 2013||Metavention, Inc.||Methods for thermally-induced hepatic neuromodulation|
|US8579891||7 Mar 2013||12 Nov 2013||Metavention, Inc.||Devices for thermally-induced hepatic neuromodulation|
|US8612022||13 Sep 2012||17 Dec 2013||Invatec S.P.A.||Neuromodulation catheters and associated systems and methods|
|US8620423 *||14 Mar 2011||31 Dec 2013||Medtronic Ardian Luxembourg S.A.R.L.||Methods for thermal modulation of nerves contributing to renal function|
|US8622937||8 Oct 2008||7 Jan 2014||Kona Medical, Inc.||Controlled high efficiency lesion formation using high intensity ultrasound|
|US8626300 *||11 Mar 2011||7 Jan 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for thermally-induced renal neuromodulation|
|US8652129||21 Aug 2009||18 Feb 2014||Medtronic Ardian Luxembourg S.A.R.L.||Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation|
|US8676309||28 Jun 2013||18 Mar 2014||Medtronic Ardian Luxembourg S.A.R.L.||Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction|
|US8684998||9 Mar 2012||1 Apr 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for inhibiting renal nerve activity|
|US8715209||12 Apr 2012||6 May 2014||Kona Medical, Inc.||Methods and devices to modulate the autonomic nervous system with ultrasound|
|US8721637||12 Jul 2013||13 May 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons|
|US8725249||8 Mar 2012||13 May 2014||Nephera Ltd.||Stimulation of the urinary system|
|US8728069||23 Oct 2013||20 May 2014||Metavention, Inc.||Modulation of nerves that innervate the liver|
|US8728070||23 Oct 2013||20 May 2014||Metavention, Inc.||Hepatic neuromodulation methods|
|US8728075||30 Aug 2010||20 May 2014||Medtronic Ardian Luxembourg S.A.R.L.||Multi-directional deflectable catheter apparatuses, systems, and methods for renal neuromodulation|
|US8728137||12 Feb 2013||20 May 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for thermally-induced renal neuromodulation|
|US8728138||12 Feb 2013||20 May 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for thermally-induced renal neuromodulation|
|US8731672||18 Jun 2013||20 May 2014||Holaira, Inc.||System and method for bronchial dilation|
|US8740895||28 Jun 2013||3 Jun 2014||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US8740896||12 Jul 2013||3 Jun 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for performing renal neuromodulation via catheter apparatuses having inflatable balloons|
|US8758334||1 Nov 2013||24 Jun 2014||Metavention, Inc.||Hepatic neuromodulation devices|
|US8768470||11 May 2010||1 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for monitoring renal neuromodulation|
|US8771252||20 May 2005||8 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and devices for renal nerve blocking|
|US8774913||14 Nov 2006||8 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for intravasculary-induced neuromodulation|
|US8774922||21 May 2013||8 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods|
|US8777942||22 Oct 2010||15 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation|
|US8777943||28 Jun 2013||15 Jul 2014||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US8784463||12 Feb 2013||22 Jul 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for thermally-induced renal neuromodulation|
|US8805545||16 Apr 2013||12 Aug 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for multi-vessel renal neuromodulation|
|US8808280||20 Apr 2012||19 Aug 2014||Holaira, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8808345||13 Apr 2010||19 Aug 2014||Medtronic Ardian Luxembourg S.A.R.L.||Handle assemblies for intravascular treatment devices and associated systems and methods|
|US8818514||2 Jul 2013||26 Aug 2014||Medtronic Ardian Luxembourg S.A.R.L.||Methods for intravascularly-induced neuromodulation|
|US8821489||20 Apr 2012||2 Sep 2014||Holaira, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8845629||5 Apr 2010||30 Sep 2014||Medtronic Ardian Luxembourg S.A.R.L.||Ultrasound apparatuses for thermally-induced renal neuromodulation|
|US8852163||28 Jun 2013||7 Oct 2014||Medtronic Ardian Luxembourg S.A.R.L.||Renal neuromodulation via drugs and neuromodulatory agents and associated systems and methods|
|US8870863||28 May 2010||28 Oct 2014||Medtronic Ardian Luxembourg S.A.R.L.||Catheter apparatuses, systems, and methods for renal neuromodulation|
|US8876815||11 Jun 2014||4 Nov 2014||Metavention, Inc.||Energy delivery devices for hepatic neuromodulation|
|US8880185||25 Jun 2013||4 Nov 2014||Boston Scientific Scimed, Inc.||Renal denervation and stimulation employing wireless vascular energy transfer arrangement|
|US8880186||11 Apr 2013||4 Nov 2014||Medtronic Ardian Luxembourg S.A.R.L.||Renal neuromodulation for treatment of patients with chronic heart failure|
|US8888773||11 Mar 2013||18 Nov 2014||Medtronic Ardian Luxembourg S.A.R.L.||Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods|
|US8894639||16 May 2014||25 Nov 2014||Metavention, Inc.||Hepatic artery nerve modulation methods|
|US8900223||8 Nov 2010||2 Dec 2014||Tsunami Medtech, Llc||Tissue ablation systems and methods of use|
|US8911439||11 Nov 2010||16 Dec 2014||Holaira, Inc.||Non-invasive and minimally invasive denervation methods and systems for performing the same|
|US8923970 *||9 Jun 2011||30 Dec 2014||Nephera Ltd.||Stimulation of the urinary system|
|US8932289||26 Sep 2011||13 Jan 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US8934978||22 Apr 2014||13 Jan 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for renal neuromodulation|
|US8939970||29 Feb 2012||27 Jan 2015||Vessix Vascular, Inc.||Tuned RF energy and electrical tissue characterization for selective treatment of target tissues|
|US8945107||23 Oct 2011||3 Feb 2015||Medtronic Ardian Luxembourg S.A.R.L.||Neuromodulation cryotherapeutic devices and associated systems and methods|
|US8948865||15 Nov 2013||3 Feb 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods for treating heart arrhythmia|
|US8951251||7 Nov 2012||10 Feb 2015||Boston Scientific Scimed, Inc.||Ostial renal nerve ablation|
|US8951296||14 Mar 2013||10 Feb 2015||Medtronic Ardian Luxembourg S.A.R.L.||Devices and methods for photodynamically modulating neural function in a human|
|US8956352||25 Oct 2011||17 Feb 2015||Medtronic Ardian Luxembourg S.A.R.L.||Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods|
|US8958871||14 Jan 2011||17 Feb 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach|
|US8961507||20 Apr 2012||24 Feb 2015||Holaira, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8961508||20 Apr 2012||24 Feb 2015||Holaira, Inc.||Systems, assemblies, and methods for treating a bronchial tree|
|US8974445||7 Jan 2010||10 Mar 2015||Recor Medical, Inc.||Methods and apparatus for treatment of cardiac valve insufficiency|
|US8974451||25 Oct 2011||10 Mar 2015||Boston Scientific Scimed, Inc.||Renal nerve ablation using conductive fluid jet and RF energy|
|US8983595||21 Nov 2013||17 Mar 2015||Medtronic Ardian Luxembourg S.A.R.L.||Renal neuromodulation for treatment of patients with chronic heart failure|
|US8986211||15 Mar 2011||24 Mar 2015||Kona Medical, Inc.||Energetic modulation of nerves|
|US8986231||15 Mar 2011||24 Mar 2015||Kona Medical, Inc.||Energetic modulation of nerves|
|US8986294||4 Feb 2010||24 Mar 2015||Medtronic Ardian Luxembourg S.a.rl.||Apparatuses for thermally-induced renal neuromodulation|
|US8989859||23 Jan 2014||24 Mar 2015||Medtronic Ardian Luxembourg S.A.R.L.||Systems and methods for neuromodulation for treatment of pain and other disorders associated with nerve conduction|
|US8992447||14 Jun 2012||31 Mar 2015||Kona Medical, Inc.||Energetic modulation of nerves|
|US8998894||25 Oct 2011||7 Apr 2015||Medtronic Ardian Luxembourg S.A.R.L.||Catheter apparatuses having multi-electrode arrays for renal neuromodulation and associated systems and methods|
|US9002446 *||30 Oct 2012||7 Apr 2015||Pacesetter, Inc.||Acquiring nerve activity from carotid body and/or sinus|
|US9005143||19 May 2011||14 Apr 2015||Kona Medical, Inc.||External autonomic modulation|
|US9005190||8 Nov 2013||14 Apr 2015||Metavention, Inc.||Treatment of non-alcoholic fatty liver disease|
|US9005191||8 Nov 2013||14 Apr 2015||Metavention, Inc.||Neuromodulation methods using balloon catheter|
|US9005195||26 Sep 2011||14 Apr 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US9011422||25 Sep 2014||21 Apr 2015||Metavention, Inc.||Hepatic neuromodulation to treat fatty liver conditions|
|US9014809||30 Oct 2012||21 Apr 2015||Pacesetter, Inc.||Acquiring nerve activity from carotid body and/or sinus|
|US9017317||6 Dec 2012||28 Apr 2015||Medtronic Ardian Luxembourg S.A.R.L.||Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods|
|US9017324||28 Jun 2013||28 Apr 2015||Holaira, Inc.||Delivery devices with coolable energy emitting assemblies|
|US9023034||22 Nov 2011||5 May 2015||Boston Scientific Scimed, Inc.||Renal ablation electrode with force-activatable conduction apparatus|
|US9023037||23 Apr 2013||5 May 2015||Medtronic Ardian Luxembourg S.A.R.L.||Balloon catheter apparatus for renal neuromodulation|
|US9028472||21 Dec 2012||12 May 2015||Vessix Vascular, Inc.||Methods and apparatuses for remodeling tissue of or adjacent to a body passage|
|US9028485||23 Sep 2011||12 May 2015||Boston Scientific Scimed, Inc.||Self-expanding cooling electrode for renal nerve ablation|
|US9033969||8 Nov 2013||19 May 2015||Metavention, Inc.||Nerve modulation to treat diabetes|
|US9037259||21 Dec 2012||19 May 2015||Vessix Vascular, Inc.||Methods and apparatuses for remodeling tissue of or adjacent to a body passage|
|US9044575||22 Oct 2013||2 Jun 2015||Medtronic Adrian Luxembourg S.a.r.l.||Catheters with enhanced flexibility and associated devices, systems, and methods|
|US9050106||21 Dec 2012||9 Jun 2015||Boston Scientific Scimed, Inc.||Off-wall electrode device and methods for nerve modulation|
|US9060754||23 Oct 2011||23 Jun 2015||Medtronic Ardian Luxembourg S.A.R.L.||Neuromodulation cryotherapeutic devices and associated systems and methods|
|US9060755||23 Oct 2011||23 Jun 2015||Medtronic Ardian Luxembourg S.A.R.L.||Neuromodulation cryotherapeutic devices and associated systems and methods|
|US9060761||9 Nov 2011||23 Jun 2015||Boston Scientific Scime, Inc.||Catheter-focused magnetic field induced renal nerve ablation|
|US9060784||8 Nov 2013||23 Jun 2015||Metavention, Inc.||Hepatic denervation systems|
|US9066713||23 Oct 2011||30 Jun 2015||Medtronic Ardian Luxembourg S.A.R.L.||Neuromodulation cryotherapeutic devices and associated systems and methods|
|US9066720||25 Oct 2011||30 Jun 2015||Medtronic Ardian Luxembourg S.A.R.L.||Devices, systems and methods for evaluation and feedback of neuromodulation treatment|
|US9066726||25 Apr 2013||30 Jun 2015||Medtronic Ardian Luxembourg S.A.R.L.||Multi-electrode apposition judgment using pressure elements|
|US9072527||15 Jul 2013||7 Jul 2015||Medtronic Ardian Luxembourg S.A.R.L.||Apparatuses and methods for renal neuromodulation|
|US9072902||21 Dec 2012||7 Jul 2015||Vessix Vascular, Inc.||Methods and apparatuses for remodeling tissue of or adjacent to a body passage|
|US9079000||16 Oct 2012||14 Jul 2015||Boston Scientific Scimed, Inc.||Integrated crossing balloon catheter|
|US9084609||18 Jul 2011||21 Jul 2015||Boston Scientific Scime, Inc.||Spiral balloon catheter for renal nerve ablation|
|US9084610||21 Oct 2011||21 Jul 2015||Medtronic Ardian Luxembourg S.A.R.L.||Catheter apparatuses, systems, and methods for renal neuromodulation|
|US9089350||9 Nov 2011||28 Jul 2015||Boston Scientific Scimed, Inc.||Renal denervation catheter with RF electrode and integral contrast dye injection arrangement|
|US9089541||8 Nov 2013||28 Jul 2015||Metavention, Inc.||Gastroduodenal artery neuromodulation|
|US9089542||25 Sep 2014||28 Jul 2015||Metavention, Inc.||Hepatic neuromodulation using microwave energy|
|US9095321||21 Nov 2012||4 Aug 2015||Medtronic Ardian Luxembourg S.A.R.L.||Cryotherapeutic devices having integral multi-helical balloons and methods of making the same|
|US9108040||26 Jun 2014||18 Aug 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for multi-vessel renal neuromodulation|
|US9113944||19 Nov 2012||25 Aug 2015||Tsunami Medtech, Llc||Method for performing lung volume reduction|
|US9114123||31 Oct 2014||25 Aug 2015||Metavention, Inc.||Hepatic neuromodulation using fluids or chemical agents|
|US9114124||26 Dec 2014||25 Aug 2015||Metavention, Inc.||Modulation of nerves innervating the liver|
|US9119600||15 Nov 2012||1 Sep 2015||Boston Scientific Scimed, Inc.||Device and methods for renal nerve modulation monitoring|
|US9119632||16 Nov 2012||1 Sep 2015||Boston Scientific Scimed, Inc.||Deflectable renal nerve ablation catheter|
|US9119951||20 Apr 2011||1 Sep 2015||Kona Medical, Inc.||Energetic modulation of nerves|
|US9119952||29 Oct 2012||1 Sep 2015||Kona Medical, Inc.||Methods and devices to modulate the autonomic nervous system via the carotid body or carotid sinus|
|US9125642||6 Dec 2013||8 Sep 2015||Kona Medical, Inc.||External autonomic modulation|
|US9125643||30 Apr 2014||8 Sep 2015||Holaira, Inc.||System and method for bronchial dilation|
|US9125661||17 Oct 2013||8 Sep 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods and apparatus for renal neuromodulation|
|US9125666||28 Sep 2007||8 Sep 2015||Vessix Vascular, Inc.||Selectable eccentric remodeling and/or ablation of atherosclerotic material|
|US9125667||18 Oct 2007||8 Sep 2015||Vessix Vascular, Inc.||System for inducing desirable temperature effects on body tissue|
|US9131978||23 Apr 2014||15 Sep 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods for bilateral renal neuromodulation|
|US9131983||18 Oct 2013||15 Sep 2015||Ablative Solutions, Inc.||Methods ablating tissue using a catheter-based injection system|
|US9138281||23 Sep 2013||22 Sep 2015||Medtronic Ardian Luxembourg S.A.R.L.||Methods for bilateral renal neuromodulation via catheter apparatuses having expandable baskets|
|US9138292||9 Oct 2014||22 Sep 2015||Medtronic Ardian Luxembourg S.A.R.L.||Multi-electrode catheter assemblies for renal neuromodulation and associated systems and methods|
|US9138578||10 Sep 2013||22 Sep 2015||Medtronic Ardian Luxembourg S.A.R.L.||Endovascular catheters with tuned control members and associated systems and methods|
|US20060025821 *||20 May 2005||2 Feb 2006||Mark Gelfand||Methods and devices for renal nerve blocking|
|US20060041277 *||25 Jul 2005||23 Feb 2006||Mark Deem||Methods and apparatus for renal neuromodulation|
|US20060212076 *||6 Mar 2006||21 Sep 2006||Ardian, Inc.||Methods and apparatus for treating end-stage renal disease|
|US20060212078 *||6 Mar 2006||21 Sep 2006||Ardian, Inc.||Methods and apparatus for treating congestive heart failure|
|US20060222667 *||1 Jun 2006||5 Oct 2006||The Foundry, Inc.||Apparatus for treating asthma using neurotoxin|
|US20060265014 *||6 Mar 2006||23 Nov 2006||Ardian, Inc.||Methods and apparatus for bilateral renal neuromodulation|
|US20060265015 *||13 Apr 2006||23 Nov 2006||Ardian, Inc.||Methods and apparatus for monopolar renal neuromodulation|
|US20060271111 *||6 Mar 2006||30 Nov 2006||Ardian, Inc.||Methods and apparatus for treating contrast nephropathy|
|US20110208096 *||25 Aug 2011||Ardian, Inc.||Methods and apparatus for thermally-induced renal neuromodulation|
|US20110257564 *||20 Oct 2011||Ardian, Inc.||Methods for thermal modulation of nerves contributing to renal function|
|US20110301662 *||8 Dec 2011||Nephera Ltd.||Stimulation of the urinary system|
|US20130296443 *||6 Mar 2013||7 Nov 2013||Enigma Medical, Inc.||System and method of trans-venous pre-aortic ganglion ablation|
|WO2012154800A1 *||9 May 2012||15 Nov 2012||St. Jude Medical, Inc.||Transvenous renal nerve modulation for treatment of hypertension, cardiovascular disorders, and chronic renal diseases|
|WO2012170258A1 *||30 May 2012||13 Dec 2012||Curtis Guy P||System and method for transvascular activation of cardiac nerves with automatic restart|
|International Classification||A61N1/18, A61N1/362, A61N1/36, A61N1/32|
|Cooperative Classification||A61M1/3627, A61B18/04, A61B2018/00577, A61B2018/00434, A61N1/326, A61N1/36114, A61N1/3627, A61M5/1723, A61N1/36007, A61N1/0551, A61M5/14276, A61M2210/1082, A61M5/142, A61B18/1492, A61N1/36117, A61N5/00, A61N1/05|
|European Classification||A61M5/142P10, A61N1/36Z, A61M5/172B, A61N1/36Z3J, A61N1/36, A61N1/32P, A61N1/32|
|29 Jun 2010||AS||Assignment|
Owner name: G&L CONSULTING, LLC,NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELFAND, MARK;LEVIN, HOWARD R.;REEL/FRAME:024611/0048
Effective date: 20041116
Owner name: FOUNDRY NEWCO 8, INC.,CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:G&L CONSULTING, LLC;REEL/FRAME:024611/0061
Effective date: 20041117
Owner name: ARDIAN, INC.,CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:FOUNDRY NEWCO 8, INC.;REEL/FRAME:024611/0090
Effective date: 20050118
Owner name: ARDIAN, INC., CALIFORNIA
Free format text: CHANGE OF NAME;ASSIGNOR:FOUNDRY NEWCO 8, INC.;REEL/FRAME:024611/0090
Effective date: 20050118
Owner name: FOUNDRY NEWCO 8, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:G&L CONSULTING, LLC;REEL/FRAME:024611/0061
Effective date: 20041117
Owner name: G&L CONSULTING, LLC, NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GELFAND, MARK;LEVIN, HOWARD R.;REEL/FRAME:024611/0048
Effective date: 20041116